Clinical Trial Update: A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for dasatinib plus rituximab in relapsed/refractory chronic lymphocytic leukemia; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Rituximab (rituximab)

Snippet

Sponsor: University of California, San Diego | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-14